Novo Nordisk's latest proposal values Metsera at up to $86.20 per share, equating to a total valuation of approximately $10 billion. This figure marks a striking 159% premium over Metsera's closing ...

Novo Nordisk CEO Mike Doustdar tells CNBC he has huge confidence in the company's pipeline as it narrows its guidance and ...

Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company ...

The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

Novo Nordisk slipped 1.8% after it raised its offer to buy drugmaker Metsera, which jumped 20.5%. Novo Nordisk is trying to outbid rival Pfizer, which fell 1.5%. European markets were mostly lower and ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...